DDInter1031 DDInter1926
Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as ledipasvir. More specifically, ledipasvir is an inhibitor of the Hepatitis C Virus (HCV) Non-Structural Protein 5A (NS5A), which is required for viral RNA replication and assembly of HCV virions. Although its exact mechanism of action is unknown, it is postulated to prevent hyperphosphorylation of NS5A which is required
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy [FDA label]. Previously, this drug was indicated only for patients with 17p gene deletion .
Venetoclax {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Venetoclax {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secobarbital
Venetoclax {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Venetoclax {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Venetoclax {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Venetoclax may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Venetoclax may lead to a major life threatening interaction when taken with Atazanavir
Venetoclax may lead to a major life threatening interaction when taken with Lorlatinib